Key Takeaways
- Eli Lilly (LLY) is set to advance its experimental amylin-based obesity drug, eloralintide, to late-stage trials next month after mid-stage results showed patients achieved up to a remarkable 20.1% weight loss, positioning the company at the forefront of the rapidly expanding obesity market.
- Seasonal retail hiring for the upcoming holiday season is projected to fall to its lowest level in 15 years, with an estimated 265,000 to 365,000 new hires, reflecting a softening labor market despite expectations for record holiday sales surpassing $1 trillion.
- A senior German military leader has issued a stark warning to NATO, indicating that Russia possesses the capability to launch a limited, regionally confined attack on NATO territory as early as "tomorrow," while also cautioning about a potential large-scale assault by 2029.
- Japan has issued a tsunami advisory for Iwate Prefecture following a powerful 6.7-magnitude offshore earthquake, prompting coastal residents to evacuate as waves up to 1 meter are anticipated.
Eli Lilly (LLY) is poised to make significant strides in the burgeoning obesity treatment market, announcing plans to commence late-stage trials next month for its experimental drug, eloralintide. This development follows highly promising mid-stage trial results, where patients experienced an average weight loss of up to 20.1% at the highest 9 mg dose over 48 weeks. The lowest 1 mg dose also demonstrated substantial efficacy, leading to a 9.5% weight reduction.
Eloralintide, a once-weekly injectable, operates by mimicking the pancreatic hormone amylin, which works to suppress hunger and slow digestion. This mechanism of action differentiates it from the current generation of GLP-1 agonists like Lilly's own Zepbound and Novo Nordisk's Wegovy, potentially offering a new therapeutic avenue with a favorable side effect profile. Analysts suggest these results place Lilly in a commanding position within the amylin treatment space, though the news led to an 11% drop in shares for competitor Zealand Pharma (ZEAL).
Meanwhile, the U.S. retail sector is bracing for a significant downturn in seasonal hiring, with projections indicating the lowest level of seasonal retail jobs in 15 years. The National Retail Federation (NRF) expects retailers to hire between 265,000 and 365,000 seasonal workers from November 1 to December 31, a notable decrease from the 442,000 hired last year. This cautious approach to staffing reflects a softening labor market and an increasing reliance on automation and existing permanent staff. Despite the reduced hiring, the NRF still anticipates a record holiday shopping season, with sales projected to surpass $1 trillion for the first time, representing a growth of 3.7% to 4.2%.
On the geopolitical front, Lieutenant-General Alexander Sollfrank, who leads Germany's joint operations command, has issued a grave warning regarding Russia's military capabilities. He stated that Russia could initiate a small-scale, regionally limited attack on NATO territory "as early as tomorrow," emphasizing that such a decision would depend on the Western allies' defensive posture. Sollfrank also reiterated earlier NATO assessments that Russia could be capable of launching a larger-scale assault against the 32-member alliance by 2029 if its rearmament efforts continue unabated. In response to these escalating tensions, Germany plans to significantly increase its defense spending to approximately €160 billion by 2029 and expand its armed forces to 260,000 troops.
In Asia, Japan's Iwate Prefecture is under a tsunami advisory following a powerful 6.7-magnitude offshore earthquake that struck around 5:03 PM local time. The Japan Meteorological Agency has warned of potential tsunami waves up to 1 meter (3 feet) high, urging residents in coastal areas to evacuate. The quake, measured at magnitude 6.8 by the U.S. Geological Survey, occurred in waters off Iwate, a region still mindful of the devastating 2011 9.0-magnitude earthquake and tsunami.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.